Heparin-Induced Thrombocytopenia in Intensive Care Patients

ABSTRACT

Heparin-induced thrombocytopenia (HIT) is a serious, prothrombotic, immune-mediated complication of heparin therapy that can cause limb- and life-threatening thromboembolic events. Prompt diagnosis and therapeutic dose anticoagulation by an alternative anticoagulant are crucial to improve clinical outcome. In critically ill patients, the diagnosis of HIT is difficult due to the high incidence of thrombocytopenia, often caused by reasons other than HIT, and the high incidence of clinically irrelevant, non-platelet-activating anti–PF4-heparin antibodies. Also, treatment of HIT is problematic in these patients. No antidote is available for any of the alternative anticoagulants, and their half-lives are often prolonged in the presence of renal or hepatic insufficiency. This increases the risk of bleeding complications and mandates careful balancing of both risks, thrombosis and bleeding. Therefore, accurate diagnosis of HIT and individual choice of alternative anticoagulant are important for the adequate management of critically ill HIT patients.

KEYWORDS

Heparin-induced thrombocytopenia - intensive care - critical care

REFERENCES

• 1 Visentin G P, Liu C Y, Aster R H. Molecular immunopathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 149-166
• 2 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 311S-337S
• 3 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 21-66
• 4 Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent J L. Time course of platelet counts in critically ill patients.  Crit Care Med. 2002;  30 753-756
• 5 Crowther M A, Cook D J, Meade M O et al.. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors.  J Crit Care. 2005;  20 348-353
• 6 Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn E G. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome.  Crit Care Med. 2002;  30 1765-1771
• 7 Warkentin T E, Roberts R S, Hirsh J, Kelton J G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.  Arch Intern Med. 2003;  163 2518-2524
• 8 Pouplard C, May M A, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies.  Br J Haematol. 2005;  128 837-841
• 9 Selleng S, Selleng K, Wollert H G et al.. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass.  J Thromb Haemost. 2008;  6 428-435
• 10 Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review.  Semin Thromb Hemost. 2006;  32 803-809
• 11 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
• 12 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost. 1998;  79 1-7
• 13 Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.  J Thromb Haemost. 2005;  3 2428-2436
• 14 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 502-507
• 15 Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin T E, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.  Thromb Haemost. 2005;  94 132-135
• 16 Warkentin T E, Greinacher A. Thrombosis of the cerebral veins and sinuses.  N Engl J Med. 2005;  353 314-315
• 17 Wester J P, Haas F J, Biesma D H, Leusink J A, Veth G. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients.  Intensive Care Med. 2004;  30 1927-1934
• 18 Amiral J, Bridey F, Dreyfus M et al.. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.  Thromb Haemost. 1992;  68 95-96
• 19 Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.  Thromb Haemost. 1994;  71 247-251
• 20 Greinacher A, Gopinadhan M, Gunther J U et al.. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.  Arterioscler Thromb Vasc Biol. 2006;  26 2386-2393
• 21 Rauova L, Poncz M, McKenzie S E et al.. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.  Blood. 2005;  105 131-138
• 22 Rauova L, Zhai L, Kowalska M A, Arepally G M, Cines D B, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.  Blood. 2006;  107 2346-2353
• 23 Warkentin T E, Cook R J, Marder V J et al.. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.  Blood. 2005;  106 3791-3796
• 24 Denomme G A. Platelet and leukocyte Fcγ receptors in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 187-208
• 25 Warkentin T E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.  Transfus Med Rev. 1996;  10 249-258
• 26 Arepally G M, Poncz M, Cines D B. Immune vascular injury in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 209-225
• 27 Warkentin T E. Heparin-induced thrombocytopenia: a clinicopathologic syndrome.  Thromb Haemost. 1999;  82 439-447
• 28 Warkentin T E, Sheppard J A, Moore J C, Moore K M, Sigouin C S, Kelton J G. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?.  J Lab Clin Med. 2005;  146 341-346
• 29 Warkentin T E, Sheppard J A. Testing for heparin-induced thrombocytopenia antibodies.  Transfus Med Rev. 2006;  20 259-272
• 30 Warkentin T E, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 227-260
• 31 Prechel M, Walenga J M. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.  Semin Thromb Hemost. 2008;  34 86-96
• 32 Greinacher A, Juhl D, Strobel U et al.. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.  J Thromb Haemost. 2007;  5 1666-1673
• 33 Lo G K, Sigouin C S, Warkentin T E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?.  Am J Hematol. 2007;  82 1037-1043
• 34 Lo G K, Juhl D, Warkentin T E, Sigouin C S, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.  J Thromb Haemost. 2006;  4 759-765
• 35 Greinacher A, Warkentin T E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 283-317
• 36 Lee D H, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 67-116
• 37 Martel N, Lee J, Wells P S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.  Blood. 2005;  106 2710-2715
• 38 Warkentin T E, Sheppard J A, Sigouin C S, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia.  Blood. 2006;  108 2937-2941
• 39 Pohl C, Kredteck A, Bastians B, Hanfland P, Klockgether T, Harbrecht U. Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin.  Neurology. 2005;  64 1285-1287
• 40 Lindhoff-Last E, Nakov R, Misselwitz F, Breddin H K, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.  Br J Haematol. 2002;  118 1137-1142
• 41 Morris T A, Castrejon S, Devendra G, Gamst A C. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.  Chest. 2007;  132 1131-1139
• 42 Schenk S, El Banayosy A, Prohaska W et al.. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support.  J Thorac Cardiovasc Surg. 2006;  131 1373-1381
• 43 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
• 44 Greinacher A, Eichler P, Lietz T, Warkentin T E. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia.  Blood. 2005;  106 2921-2922
• 45 Verma A K, Levine M, Shalansky S J, Carter C J, Kelton J G. Frequency of heparin-induced thrombocytopenia in critical care patients.  Pharmacotherapy. 2003;  23 745-753
• 46 Cook D, Crowther M, Meade M et al.. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.  Crit Care Med. 2005;  33 1565-1571
• 47 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery.  Ann Thorac Surg. 2003;  76 2121-2131
• 48 Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).  Thromb Haemost. 2008;  99 779-781
• 49 Warkentin T E, Maurer B T, Aster R H. Heparin-induced thrombocytopenia associated with fondaparinux.  N Engl J Med. 2007;  356 2653-2655
• 50 Bartholomew J R. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 379-408
• 51 Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.  Expert Rev Cardiovasc Ther. 2004;  2 339-357
• 52 Lindhoff-Last E, Piechottka G P, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level.  Thromb Res. 2000;  100 55-60
• 53 Lange U, Nowak G, Bucha E. Ecarin chromogenic assay—a new method for quantitative determination of direct thrombin inhibitors like hirudin.  Pathophysiol Haemost Thromb. 2003;  33 184-191
• 54 Warkentin T E, Greinacher A, Craven S, Dewar L, Sheppard J A, Ofosu F A. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.  Thromb Haemost. 2005;  94 958-964
• 55 Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.  Blood. 2004;  104 3072-3077
• 56 Tardy B, Lecompte T, Boelhen F et al.. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.  Blood. 2006;  108 1492-1496
• 57 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.  Circulation. 2003;  108 2062-2065
• 58 Greinacher A, Warkentin T E. The direct thrombin inhibitor hirudin.  Thromb Haemost. 2008;  99 819-829
• 59 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
• 60 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
• 61 Lewis B E, Wallis D E, Hursting M J, Levine R L, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.  Chest. 2006;  129 1407-1416
• 62 Lewis B E, Hursting M J. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 379-408
• 63 Kiser T H, Jung R, MacLaren R, Fish D N. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.  Pharmacotherapy. 2005;  25 1736-1745
• 64 Beiderlinden M, Treschan T A, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients.  Ann Pharmacother. 2007;  41 749-754
• 65 Kodityal S, Nguyen P H, Kodityal A, Sherer J, Hursting M J, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital.  J Intensive Care Med. 2006;  21 86-92
• 66 Hoffman W D, Czyz Y, McCollum D A, Hursting M J. Reduced argatroban doses after coronary artery bypass graft surgery.  Ann Pharmacother. 2008;  42 309-316
• 67 Warkentin T E, Greinacher A, Koster A. Bivalirudin.  Thromb Haemost. 2008;  99 830-839
• 68 Mann M J, Tseng E, Ratcliffe M et al.. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.  J Heart Lung Transplant. 2005;  24 222-225
• 69 Kiser T H, Fish D N. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.  Pharmacotherapy. 2006;  26 452-460
• 70 Chong B H, Gallus A S, Cade J F et al.. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.  Thromb Haemost. 2001;  86 1170-1175
• 71 Chong B H, Magnani H N. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 295-318
• 72 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.  Thromb Haemost. 2001;  85 950-957
• 73 Lubenow N, Warkentin T E, Greinacher A et al.. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.  Thromb Res. 2006;  117 507-515
• 74 Tardy-Poncet B, Tardy B, Reynaud J et al.. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.  Chest. 1999;  115 1616-1620
• 75 Efird L E, Kockler D R. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.  Ann Pharmacother. 2006;  40 1383-1387
• 76 Lobo B L. Use of newer anticoagulants in patients with chronic kidney disease.  Am J Health Syst Pharm. 2007;  64 2017-2026
• 77 Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.  Clin Pharmacol Ther. 2002;  71 433-439
• 78 Fischer K G. Hirudin in renal insufficiency.  Semin Thromb Hemost. 2002;  28 467-482
• 79 Frank R D, Farber H, Stefanidis I, Lanzmich R, Kierdorf H P. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes.  Kidney Int Suppl. 1999;  72 S41-S45
• 80 Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.  Thromb Res. 2001;  101 145-157
• 81 Ibbotson S H, Grant P J, Kerry R, Findlay V S, Prentice C R. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro.  Thromb Haemost. 1991;  65 64-66
• 82 Yee A J, Kuter D J. Successful recovery after an overdose of argatroban.  Ann Pharmacother. 2006;  40 336-339
• 83 Warkentin T E, Cook D J. Heparin, low molecular weight heparin, and heparin-induced thrombocytopenia in the ICU.  Crit Care Clin. 2005;  21 513-529
• 84 Napolitano L M, Warkentin T E, Almahameed A, Nasraway S A. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management.  Crit Care Med. 2006;  34 2898-2911
• 85 Huhle G, Geberth M, Hoffmann U, Heene D L, Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.  Gynecol Obstet Invest. 2000;  49 67-69
• 86 Eriksson B I, Wille-Jorgensen P, Kalebo P et al.. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med. 1997;  337 1329-1335
• 87 Eriksson B I. New therapeutic options in deep vein thrombosis prophylaxis.  Semin Hematol. 2000;  37 7-9
• 88 Fischer K-G. Hemodialysis in Heparin-Induced Thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 463-485
• 89 Murray P T, Reddy B V, Grossman E J et al.. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.  Kidney Int. 2004;  66 2446-2453
• 90 de Pont A C, Hofstra J J, Pik D R, Meijers J C, Schultz M J. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.  Crit Care. 2007;  11 R102
• 91 Tang I Y, Cox D S, Patel K et al.. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.  Ann Pharmacother. 2005;  39 231-236
• 92 Horne M K, McCloskey D J, Calis K, Wesley R, Childs R, Kasten-Sportes C. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices.  Pharmacotherapy. 2006;  26 1262-1267